CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer

Lei Nie(The University of Texas MD Anderson Cancer Center), Mien‐Chie Hung(The University of Texas MD Anderson Cancer Center), Baozhen Ke(The University of Texas MD Anderson Cancer Center), Jun Yao(The University of Texas MD Anderson Cancer Center), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center), Jennifer L. Hsu(The University of Texas MD Anderson Cancer Center), Cihui Zhu(The University of Texas MD Anderson Cancer Center), Yi‐Hsin Hsu(The University of Texas MD Anderson Cancer Center), Nancy E. Davidson(Johns Hopkins University), Rong Deng(The University of Texas MD Anderson Cancer Center), Celina G. Kleer(University of Michigan), Xixi Zhao(The University of Texas MD Anderson Cancer Center), Li-Chuan Chan(The University of Texas MD Anderson Cancer Center), Jung-Mao Hsu(The University of Texas MD Anderson Cancer Center), Hirohito Yamaguchi(Qatar Foundation), Fei Zhang(Shanghai Jiao Tong University), Ye Han(Sungkyunkwan University), Yi Yang(The University of Texas MD Anderson Cancer Center), Wan-Chi Lin(The University of Texas MD Anderson Cancer Center), Jun Tang(Hubei University of Medicine), Yu‐Yi Chu(National Cheng Kung University), Junwei Hou(Institute of Microbiology), Yongkun Wei(The University of Texas MD Anderson Cancer Center), How-Wen Ko(University of Houston), Dean Pan(Austin College), Weiya Xia(The University of Texas MD Anderson Cancer Center), Longfei Huo(The University of Texas MD Anderson Cancer Center)
Nature Communications
November 8, 2019
Cited by 99


Related Papers